Identification of potential drugs for Parkinson's disease based on a sub-pathway method

References

• Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann NY Acad Sci 2003;991:120–31.
   PubMed Web of Science ®Google Scholar
• Ryu EJ, Harding HP, Angelastro JM, et al. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci 2002;22(24):10690–8.
   PubMed Web of Science ®Google Scholar
• Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S16–23; discussion S-5. doi:10.1002/ana.10487.
   PubMed Web of Science ®Google Scholar
• Deng H, Yuan L. Genetic variants and animal models in SNCA and Parkinson disease. Ageing Res Rev 2014;15C:161–76. doi:10.1016/j.arr.2014.04.002.
   Web of Science ®Google Scholar
• Hashimoto M, Rockenstein E, Mante M, et al. Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 2001;32(2):213–23.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Perlstein EO, Imarisio S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol 2007;3(6):331–8. doi:10.1038/nchembio883.
   PubMed Web of Science ®Google Scholar
• Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2012;2(1):a008888. doi:10.1101/cshperspect.a008888.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang H. Environmental toxins and alpha-synuclein in Parkinson's disease. Mol Neurobiol 2005;31(1–3):273–82. doi:10.1385/MN:31:1-3:273.
   PubMed Web of Science ®Google Scholar
• Tufekci KU, Meuwissen R, Genc S, et al. Inflammation in Parkinson's disease. Adv Protein Chem Struct Biol 2012;88:69–132. doi:10.1016/B978-0-12-398314-5.00004-0.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. Jama 2014;311(16):1670–83. doi:10.1001/jama.2014.3654.
   PubMed Web of Science ®Google Scholar
• Bender DA, Earl CJ, Lees AJ. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. Clin Sci (Lond) 1979;56(1):89–93.
   PubMed Web of Science ®Google Scholar
• Bender DA. Effects of benserazide, carbidopa and isoniazid administration on tryptophan-nicotinamide nucleotide metabolism in the rat. Biochem Pharmacol 1980;29(15):2099–104.
   PubMed Web of Science ®Google Scholar
• Cerasa A, Fasano A, Morgante F, et al. Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology. Front Neurol 2014;5:49. doi:10.3389/fneur.2014.00049.
   PubMedGoogle Scholar
• Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998;339(16):1130–43. doi:10.1056/NEJM199810153391607.
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313(5795):1929–35.
   PubMed Web of Science ®Google Scholar
• Lesnick TG, Papapetropoulos S, Mash DC, et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 2007;3(6):e98. doi:10.1371/journal.pgen.0030098.
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S, Ffrench-Mullen J, McCorquodale D, et al. Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease. Gene Exp 2006;13(3):205–15.
   PubMed Web of Science ®Google Scholar
• Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol 2009;53(3):254–63. doi:10.1016/j.jacc.2008.08.072.
   PubMed Web of Science ®Google Scholar
• Li C, Shang D, Wang Y, et al. Characterizing the network of drugs and their affected metabolic subpathways. PLoS One 2012;7(10):e47326. doi:10.1371/journal.pone.0047326.
   Google Scholar
• Peter D, Liu Y, Sternini C, et al. Differential expression of two vesicular monoamine transporters. J Neurosci 1995;15(9):6179–88.
   PubMed Web of Science ®Google Scholar
• Brighina L, Riva C, Bertola F, et al. Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease. Neurobiol Aging 2013;34(6):e9–13. doi:10.1016/j.neurobiolaging.2012.12.020.
   Google Scholar
• Sala G, Brighina L, Saracchi E, et al. Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease. J Neural Transm 2010;117(9):1093–8. doi:10.1007/s00702-010-0446-z.
   PubMed Web of Science ®Google Scholar
• Glatt CE, Wahner AD, White DJ, et al. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 2006;15(2):299–305. doi:10.1093/hmg/ddi445.
   PubMed Web of Science ®Google Scholar
• Cellini B, Montioli R, Oppici E, Voltattorni CB. Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overview. Open Biochem J 2012;6:131–8. doi:10.2174/1874091×01206010131.
   PubMedGoogle Scholar
• Li C, Shang D, Wang Y, et al. Characterizing the network of drugs and their affected metabolic subpathways. PLoS One 2012;7(10):e47326.
   Google Scholar
• Fitzpatrick FA, Soberman R. Regulated formation of eicosanoids. J Clin Invest 2001;107(11):1347–51. doi:10.1172/JCI13241.
   PubMed Web of Science ®Google Scholar
• Nilsson CL, Hellstrand M, Ekman A, Eriksson E. Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent. Br J Pharmacol 1998;124(8):1651–8. doi:10.1038/sj.bjp.0702025.
   PubMed Web of Science ®Google Scholar
• Basselin M, Chang L, Bell JM, Rapoport SI. Chronic lithium chloride administration to unanesthetized rats attenuates brain dopamine D2-like receptor-initiated signaling via arachidonic acid. Neuropsychopharmacology 2005;30(6):1064–75. doi:10.1038/sj.npp.1300671.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee AK, Chang L, Lee HJ, et al. D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats. Psychopharmacology (Berl) 2005;180(4):735–42. doi:10.1007/s00213-005-2208-4.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee AK, Chang L, White L, et al. D-Amphetamine stimulates D2 dopamine receptor-mediated brain signaling involving arachidonic acid in unanesthetized rats. J Cereb Blood Flow Metab 2006;26(11):1378–88. doi:10.1038/sj.jcbfm.9600290.
   PubMed Web of Science ®Google Scholar
• Haavik J, Toska K. Tyrosine hydroxylase and Parkinson's disease. Mol Neurobiol 1998;16(3):285–309. doi:10.1007/BF02741387.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang J, Zeng Y. Overview of tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug Targets 2012;11(4):350–8.
   PubMed Web of Science ®Google Scholar
• Rambour M, Moreau C, Salleron J, et al. Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients. Rev Neurol (Paris) 2014;170(3):205–15. doi:10.1016/j.neurol.2013.10.012.
   PubMed Web of Science ®Google Scholar
• Sobel JD. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 1986;315(23):1455–8. doi:10.1056/NEJM198612043152305.
   PubMed Web of Science ®Google Scholar
• Parsanezhad ME, Alborzi S, Pakniat M, Schmidt EH. A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome. Fertil Steril 2003;80(5):1151–5.
   PubMed Web of Science ®Google Scholar
• Li X, Song X, Kamenecka TM, Cameron MD. Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5. Drug Metab Dispos 2012;40(9):1803–9. doi:10.1124/dmd.112.046144.
   PubMed Web of Science ®Google Scholar
• Halabe Bucay A. Activation of the proopiomelanocortin gene with ketoconazole as a treatment for Parkinson's disease: a new hypothesis. Ann NY Acad Sci 2008;1144:237–42. doi:10.1196/annals.1418.013.
   PubMed Web of Science ®Google Scholar
• Richards DM, Brogden RN, Heel RC, et al. Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1984;28(1):38–61.
   PubMed Web of Science ®Google Scholar
• Karapetyan YE, Sferrazza GF, Zhou M, et al. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proc Natl Acad Sci USA 2013;110(17):7044–9. doi:10.1073/pnas.1303510110.
   PubMed Web of Science ®Google Scholar
• Lynch-Day MA, Mao K, Wang K, et al. The role of autophagy in Parkinson's disease. Cold Spring Harb Perspect Med 2012;2(4):a009357. doi:10.1101/cshperspect.a009357.
   PubMed Web of Science ®Google Scholar
• Searles Nielsen S, Bammler TK, Gallagher LG, et al. Genotype and age at Parkinson disease diagnosis. Int J Mol Epidemiol Genet 2013;4(1):61–9.
   PubMedGoogle Scholar
• Lucero ML, Gonzalo A, Mumford R, et al. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol 2012;35(Suppl 1):18–24. doi:10.3109/01480545.2012.682651.
   PubMed Web of Science ®Google Scholar